ProCE Banner Activity

NADIA: Wk 96 Results With DTG vs DRV/RTV and TDF vs ZDV as Second-line ART in Africa

Slideset Download
Conference Coverage
This trial supports use of DTG + 2 NRTIs as second-line ART, even if NRTIs are predicted to have no activity, but resistance is a concern.

Released: February 18, 2022

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Cepheid

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare